Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 580 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (acute phase) Clear all
Not listed Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19

NCT04469179
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal Saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami Beach, Florida • Omaha, Nebraska • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness

NCT04610047
View directory record Official record
Conditions
Influenza, Influenza -Like Illness
Interventions
Norketotifen, Placebo
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • DeBary, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment

NCT03063606
View directory record Official record
Conditions
Binge-Eating Disorder, Obesity
Interventions
Cognitive-Behavioral Therapy (CBT), NB Medication (on-going from acute treatment)
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 14, 2026, 4:15 PM EDT
Suspended Phase 3 Interventional Accepts healthy volunteers

The Effects of Sex Hormones and Alcohol on Sleep

NCT06143059
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Ethanol, Saline
Drug
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 45 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event

NCT00552188
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
VIA-2291, Placebo
Drug
Lead sponsor
Tallikut Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Francisco, California • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

GLASSIA Infusion Rate Study

NCT01651351
View directory record Official record
Conditions
Alpha1-antitrypsin Deficiency, Healthy Volunteers
Interventions
Alpha1-proteinase inhibitor, Placebo: Human albumin 2.5%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 14, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional

A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

NCT01067859
View directory record Official record
Conditions
Acute Heart Failure
Interventions
Cinaciguat (BAY58-2667), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Birmingham, Alabama • Jacksonville, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 14, 2026, 4:15 PM EDT
Terminated Phase 3 Interventional

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

NCT03510897
View directory record Official record
Conditions
Cardiac Surgery
Interventions
teprasiran, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 14, 2026, 4:15 PM EDT
Not listed Phase 1Phase 2 Interventional

The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19

NCT04798716
View directory record Official record
Conditions
Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
Interventions
MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
Drug
Lead sponsor
AVEM HealthCare
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Panorama City, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

NCT00503243
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Delayed and extended release mesalazine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Pharmacological Intervention Project (Fluoxetine)

NCT00027378
View directory record Official record
Conditions
Alcoholism, Depression
Interventions
fluoxetine (Prozac), Placebo plus Treatment As Usual
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
15 Years to 20 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

NCT00768079
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Benralizumab
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Springfield, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 3 Interventional

Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia

NCT00112554
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, laromustine, placebo
Drug · Other
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
24
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 14, 2026, 4:15 PM EDT
Terminated Phase 1Phase 2 Interventional

Transcranial Ultrasound in Clinical SONothrombolysis

NCT00504842
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
MRX-801, Placebo
Drug
Lead sponsor
ImaRx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2008 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

RECOVER-SLEEP: Platform Protocol

NCT06404086
View directory record Official record
Conditions
Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
Interventions
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy

NCT01198145
View directory record Official record
Conditions
Diarrhea, Gastrointestinal Complications, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sulfasalazine, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
257
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 176 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

NCT05047601
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332, Placebo for PF-07321332, Placebo for Ritonavir, Ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,954 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
64
States / cities
Pelham, Alabama • Tucson, Arizona • Fullerton, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2

NCT01976936
View directory record Official record
Conditions
Stroke, Rhabdomyolysis, Jaundice
Interventions
Low Dose Lovastatin, Placebo, High Dose Lovastatin
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01179516
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
61
States / cities
Little Rock, Arkansas • Carson, California • Cerritos, California + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

NCT03206749
View directory record Official record
Conditions
Acute Pain
Interventions
VX-150, HB/APAP, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Phoenix, Arizona • Anaheim, California • Pasadena, California + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 14, 2026, 4:15 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)

NCT04601038
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Memory Impairment
Interventions
CORT108297, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
55 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 14, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional

INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD

NCT05163717
View directory record Official record
Conditions
Agitation in Adolescents and Young Adults With ASD
Interventions
INP105, Placebo
Combination Product
Lead sponsor
Impel Pharmaceuticals
Industry
Eligibility
12 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Portland, Maine • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

NCT02924727
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
LCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan, Placebo of valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

NCT01497223
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
MGCD290
Drug
Lead sponsor
MethylGene Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • Lake Worth, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 14, 2026, 4:15 PM EDT